ASC30
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity
Ascletis Pharma (China) Co · Phase 1/2 · Completed · Enrollment 115
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| SAD Cohort 1 | n/r | n/r | n/r | n/r |
| SAD Cohort 2 | n/r | n/r | n/r | n/r |
| SAD Cohort 3 | n/r | n/r | n/r | n/r |
| SAD Cohort 4 | n/r | n/r | n/r | n/r |
| SAD Cohort 5 | n/r | n/r | n/r | n/r |
| SAD Cohort 6 | n/r | n/r | n/r | n/r |
| SAD Cohort 7 | n/r | n/r | n/r | n/r |
| SAD Cohort 8 | n/r | n/r | n/r | n/r |
| MAD Cohort 1 | n/r | n/r | n/r | n/r |
| MAD Cohort 2 | n/r | n/r | n/r | n/r |
| MAD Cohort 3 | n/r | n/r | n/r | n/r |
Not shown
- SAD Cohort 1: endpoint not reported
- SAD Cohort 2: endpoint not reported
- SAD Cohort 3: endpoint not reported
- SAD Cohort 4: endpoint not reported
- SAD Cohort 5: endpoint not reported
- SAD Cohort 6: endpoint not reported
- SAD Cohort 7: endpoint not reported
- SAD Cohort 8: endpoint not reported
- MAD Cohort 1: endpoint not reported
- MAD Cohort 2: endpoint not reported
- MAD Cohort 3: endpoint not reported